Skip to content

Clinical Assessment of Complementary Treatment with Qishen Yiqi Dripping Pills on Ischemic Heart Failure: A Multicenter Prospective Cohort Study

Clinical assessment and promotion of TCM differential diagnosis and treatment program for ischemic heart failure

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONRC-14004407
Enrollment
Unknown
Registered
2014-02-25
Start date
2014-03-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic heart failure

Interventions

Treatment Group:Standard treatment plus Qishen Yiqi Dripping Pills (0.52g tid).

Sponsors

First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with ischemic heart failure: 1. prior or current symptoms of HFsuch as dyspnea, fatigue and fluid retention (edema) etc; 2. history of old myocardial infarction with or without percutaneous coronary intervention (PCI) or/and coronary artery bypass grafting (CABG); Coronary angiography (CAG) or coronary CTA shows stenosis of 50% or morein at least one of the main coronary arteries with or without revascularization, of which the researcher thinks that it is closely related to heart failure; 3. LVEF less than or equal to 50% measured by echocardiography in modified Simpson method; 4. New York Heart Association (NYHA) Class II to IV; 5. received standardized western medicine therapy for IHF and currently in a stable condition; 6. Submitted informed consent.

Exclusion criteria

Exclusion criteria: 1. Acute heart failure; 2. Acute coronary syndrome; 3. Preparation for revascularization therapy within a month; 4. Preparation for heart transplantation; 5. Already received or preparing to receive cardiac resynchronization therapy (CRT); 5. Already implanted or having indications to implant cardiac pacemaker; 6. Special treatments should be used for patients with comorbidities such as severe liver or renal failure and malignant tumor which could influence the clinical treatment of ischemic heart failure; 7. Pregnant or breastfeeding women, or women at childbearing age without reliable methods of contraception; 8. Participated in other trials within 2 months; Suspected or definite allergy to intervention drugs.

Design outcomes

Primary

MeasureTime frame
Minnesota life quality scale of heart failure,;NYHA cardiac function classification;

Secondary

MeasureTime frame
the scores from the four TCM diagnostic method;complex endpoints (all-cause death, frequency of re-admission due to cardiovascular disease, frequency of emergency/re-admission to hospital due to IHF, acute coronary syndrome, severe arrhythmia, cardiac shock, revascularization, stroke, pulmonary embolism and peripheral vascular incidences,etc.);echocardiography;cardiothoracic ratio(CR);

Countries

China

Contacts

Public ContactJingyuan Mao

First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

jymao@126.com+86 022 27432325

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 23, 2026